<DOC>
	<DOCNO>NCT00269815</DOCNO>
	<brief_summary>The purpose study evaluate long-term safety effectiveness OROSÂ® Methylphenidate HCl ( central nervous system stimulant ) child attention deficit hyperactivity disorder ( ADHD ) .</brief_summary>
	<brief_title>Long-term Safety Effectiveness OROS Methylphenidate HCl Children With Attention Deficit Hyperactivity Disorder</brief_title>
	<detailed_description>Attention Deficit Hyperactivity Disorder ( ADHD ) represent common neurobehavioral disorder child , affect 3 % 5 % school-age population . Behavioral pediatrician , child psychiatrist , child neurologist indicate referral ADHD may constitute 50 % practice . This multicenter , open-label , non-randomized , single-treatment study child 6 13 year age ADHD successfully complete specific earlier ALZA study . Part I study evaluate safety effectiveness OROS® ( methylphenidate HCl ) period one year child ADHD . Part II study continue evaluation safety effectiveness OROS® ( methylphenidate HCl ) child ADHD complete one year Part I study . During Part I study , patient assign treatment OROS® ( methylphenidate HCl ) 18 , 36 , 54 milligram daily , determine result participation earlier ALZA study . Patients continue Part II study continue receive daily dose determined dose end Part I. Doses titrate , consider appropriate medical personnel study site , maximum once-daily dose 54 milligram . Effectiveness determine standardized measurement attention , behavior , hyperactivity include : IOWA ( Inattention Overactivity Aggression ) Conners Rating Scale , Inattention/Overactivity ( I/O ) Oppositional/Defiance ( O/D ) subscales ; Peer Interaction assessment ; Global evaluation effectiveness therapy ; Parent Satisfaction Questionnaire . Safety evaluation include incidence adverse event , physical examination , clinical laboratory test , vital sign , sleep quality , appetite , presence/severity tic ( hard-to-control , repeat twitch part body hard-to-control repeat sound word ) . Data summarize formal hypothesis test . Part I : A daily morning oral dose 18 , 36 , 54 milligram OROS® ( methylphenidate HCl ) 12 month . Part II : Continuation 15 month daily dose take end Part I . Total treatment duration approximately 27 month .</detailed_description>
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>Patients successfully complete one follow early ALZA study : CR005992 , C97033 ( successfully complete C98011 ) , CR005989 , CR005995 , without significant drugrelated adverse event whose primary care physician agree appropriate participate study agree take OROS® ( methylphenidate HCl ) supply methylphenidate dosage form medication treatment ADHD study able comply study visit schedule whose parent ( ) teacher willing able complete protocolspecified assessment normal urinalysis , hematological blood chemistry value , value outside normal range , determine clinically significant investigator Patients clinically significant gastrointestinal problem , include narrow gastrointestinal tract coexist medical condition take medication likely interfere safe administration methylphenidate know hypersensitivity methylphenidate history high blood pressure blood pressure ( systolic diastolic ) equal great 95th percentile age , gender height female , begin menstruation</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>13 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ADHD</keyword>
	<keyword>Attention Deficit Hyperactivity Disorder</keyword>
	<keyword>OROS®</keyword>
	<keyword>child</keyword>
	<keyword>methylphenidate</keyword>
</DOC>